MarketsPanacea Biotec Limited PANACEABIO
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated in the browser from validated historical candles. This is descriptive research, not a buy or sell recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,262.17 | 1,289.75 | 1,240.67 |
| Cash Equivalents | 7.06 | 30.94 | 6.5 |
| Other Liabilities Total | 37.81 | 46.65 | 50.08 |
| Common Stock Total | 6.13 | 6.13 | 6.13 |
| Other Current Assets Total | 110.13 | 32.96 | 33.58 |
| Total Assets | 1,262.17 | 1,289.75 | 1,240.67 |
| Current Portof LT Debt/Capital Leases | 23.66 | 0 | 0 |
| Cash | 57.31 | 51.19 | 40.67 |
| Total Equity | 834.84 | 834.79 | 842.05 |
| Long Term Investments | 27.53 | 15.91 | 12.76 |
| Retained Earnings(Accumulated Deficit) | 828.71 | 729.83 | 738.26 |
| Total Common Shares Outstanding | 6.13 | 6.13 | 6.13 |
| Tangible Book Valueper Share Common Eq | 127.99 | 129.39 | 131.6 |
| Total Liabilities | 427.33 | 454.96 | 398.63 |
| Total Debt | 23.66 | 22.21 | 20.99 |
| Short Term Investments | 70.29 | 64.04 | 104.27 |
| Cashand Short Term Investments | 134.66 | 146.16 | 151.44 |
| Total Receivables Net | 75.46 | 138.36 | 111.36 |
| Deferred Income Tax | 23.14 | 23.28 | 22.54 |
| Accounts Receivable-Trade Net | 73.52 | 72.56 | 57.42 |
| Property/Plant/Equipment Total-Net | 653.24 | 636.9 | 634.76 |
| Minority Interest | -5.96 | -4.17 | -3.82 |
| Total Current Liabilities | 372.34 | 366.99 | 308.83 |
| Total Inventory | 192.79 | 220.58 | 182.74 |
| Total Preferred Shares Outstanding | 1.61 | 1.61 | 1.61 |
| Accounts Payable | 189.6 | 225.76 | 153.68 |
| Other Currentliabilities Total | 159.08 | 129.79 | 144.97 |
| Intangibles Net | 50.89 | 42.26 | 36 |
| Other Long Term Assets Total | 1.22 | 6.05 | 3.03 |
| Note Receivable-Long Term | 16.25 | 43.44 | 68.95 |
| Total Current Assets | 513.04 | 545.18 | 485.18 |
| Accumulated Depreciation Total | Not available | -687.91 | -656.22 |
| Accrued Expenses | Not available | 11.45 | 10.18 |
| Long Term Debt | Not available | 22.21 | 20.99 |
| Other Equity Total | Not available | 6.89 | 5.72 |
| Prepaid Expenses | Not available | 7.11 | 6.06 |
| Additional Paid-In Capital | Not available | 91.94 | 91.94 |
| Property/Plant/Equipment Total-Gross | Not available | 1,231.3 | 1,216.26 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
| Total Long Term Debt | Not available | 22.21 | 20.99 |
Valuation and ratios
Growth
Debt 5Yr CAGR %-50.79
Margins
Operating Margin 12m-2.85
Operating Margin 5y Avg54.3
Net Profit Margin 12m-1.12
Net Profit Margin 5y35.66
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio0.44
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk60.44
Recommendations
Target High647.5
Target Low293.1
Target Mean0
Target Median0
Analyst count, source and as-of date are not provided; target values should be treated as unverified.Peer comparison
Only peers present in the company profile payload are displayed.
| Symbol | Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|---|
| — | Sun Pharmaceutical Industries | INR 1,938.25 | 4.65 L | 38.4 | — |
| — | Divi's Laboratories | INR 7,365.5 | 1.96 L | 73.32 | — |
| — | Torrent Pharmaceuticals | INR 4,982.45 | 1.69 L | 72.73 | — |
| — | Cipla | INR 1,410.1 | 1.14 L | 27.57 | — |
| — | Zydus Lifesciences | INR 1,120.35 | 1.12 L | 21.19 | — |
Ownership
- Promoter
- 72.48%
- FII
- 2.31%
- Other
- 25.21%
Events
- board MeetingsAudited Results & Dividend
- board MeetingsAudited Results & Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingA.G.M.
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingA.G.M.
- board MeetingsQuarterly Results
- board MeetingsAudited Results
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Panacea Biotec Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks Markets Mojo
Panacea Biotec Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals Markets Mojo
Panacea Biotec Q4 FY26: Losses Return as Operating Margins Collapse Despite Revenue Growth Markets Mojo
Panacea Biotec narrows FY26 loss, passes over dividend scanx.trade
Panacea Biotec reports consolidated net profit of Rs 0.52 crore in the March 2026 quarter Business Standard
Panacea Biotec Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 marketscreener.com
Business information
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and pharmaceutical formulations and nutrition. Panacea Biotec specializes in complex generics, vaccines, and novel drug delivery platforms. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRun full, ChilRun 7+ and ChilRun full NoSucrose.
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- Website
- Not available
- Address
- Not available
- NSE Code
- PANACEABIO
- BSE Code
- 531349
AI analysis
This repository contains no authenticated model-inference API, model version, confidence distribution or forecast timestamp. The Android listing is available; verify report availability, entitlement and pricing inside the app.
Open Google PlayStock FAQ
What is the symbol and ISIN of Panacea Biotec?
Panacea Biotec has the symbol PANACEABIO and ISIN - INE922B01023.
What is the current price of Panacea Biotec?
Panacea Biotec is currently trading at INR 466.00.
What are the year high and year low of Panacea Biotec?
Panacea Biotec has a year high of INR 647.50 and a year low of INR 293.10.
What is the market capitalization of Panacea Biotec?
Panacea Biotec has a market capitalization of INR 2,811.95 crore.
What is the P/E ratio of Panacea Biotec?
Panacea Biotec has a P/E ratio of NA.
What is the dividend yield of Panacea Biotec?
Panacea Biotec has a dividend yield of 0.00%.
How is the financial performance of Panacea Biotec based on revenue, net income, and EPS?
Panacea Biotec has revenue of INR 6,397.70 crore, net income of INR -53.70 crore, and EPS of INR -2.91.
What is the book value of Panacea Biotec?
Panacea Biotec has a book value of INR 127.99.
What is the debt-to-equity ratio of Panacea Biotec?
Panacea Biotec has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Panacea Biotec?
Panacea Biotec has a price-to-book ratio of 3.64 and a price-to-sales ratio of 0.44.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.
